DR
Live price temporarily unavailable.
Bright Minds Biosciences Inc (DRUG) is a Health Care company in the Russell 2000. Latest news and coverage below.
Recent News (20)
-
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for …
-
US sanctions hindered Brazil probe into alleged drug gang associate, police head says US sanctions hindered Brazil probe into alleged drug gang associate, police head says Reuters
-
Colombia’s Petro discusses anti-drug efforts, sanctions list with Trump
Colombia’s Petro discusses anti-drug efforts, sanctions list with Trump
-
-
Brazilian police target suspects sanctioned by US over PCC drug gang links, sources say
Brazilian police target suspects sanctioned by US over PCC drug gang links, sources say
-
-
Sky Labs Showcases 'CART BP pro' for Potential Use in Drug Clinical Trials on Global Stage BASEL, Switzerland and SEOUL, South Korea, July 3, 2026 /PRNewswire/ -- Sky Labs (CEO Jack Byunghwan Lee) announced on the 2nd that it introduced its data platform business at the 9th Digital Biomarke…
-
ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug Stocktwits
-
-
How Labour diverted billions from NHS services to appease Trump – The Latest
The NHS will divert billions of pounds from essential services to pay for new medicines, under the terms of the US-UK trade deal agreed in December, which could lead to more than 200,000 excess deaths…
-
Outsourcing gap widens: Europe pulls away from US in new drug manufacturing Outsourcing gap widens: Europe pulls away from US in new drug manufacturing
-
Takeda, Insilico Strike AI Drug-Discovery Deal Worth Up to $600 Million Takeda, Insilico Strike AI Drug-Discovery Deal Worth Up to $600 Million
-
What Does Truist’s New Analyst Think About Exelixis (EXEL) and Its Next-Generation Cancer Drug? What Does Truist’s New Analyst Think About Exelixis (EXEL) and Its Next-Generation Cancer Drug?
-
-
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
-
BofA raises Merck stock price target to $141 on cancer drug potential BofA raises Merck stock price target to $141 on cancer drug potential Investing.com Nigeria
-
Johnson & Johnson (JNJ) Could Be 31% Below Fair Value After Cancer Drug Progress Johnson & Johnson (JNJ) Could Be 31% Below Fair Value After Cancer Drug Progress simplywall.st
-
-
-
Pfizer, Innovent GLP-1 drugs clear China insurance hurdle Pfizer, Innovent GLP-1 drugs clear China insurance hurdle Reuters